Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Total Non-Current Liabilities (2016 - 2025)

Gsk has reported Total Non-Current Liabilities over the past 10 years, most recently at $31.6 billion for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $31.6 billion for Q4 2025, changed 0.18% from a year ago — trailing twelve months through Dec 2025 was $31.6 billion (changed 0.18% YoY), and the annual figure for FY2025 was $31.6 billion, changed 0.18%.
  • Total Non-Current Liabilities for Q4 2025 was $31.6 billion at Gsk, roughly flat from $31.7 billion in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for GLAXF hit a ceiling of $46.0 billion in Q4 2021 and a floor of $31.2 billion in Q4 2023.
  • Median Total Non-Current Liabilities over the past 5 years was $31.7 billion (2024), compared with a mean of $34.5 billion.
  • Biggest five-year swings in Total Non-Current Liabilities: plummeted 30.47% in 2022 and later increased 1.51% in 2024.
  • Gsk's Total Non-Current Liabilities stood at $46.0 billion in 2021, then plummeted by 30.47% to $32.0 billion in 2022, then dropped by 2.33% to $31.2 billion in 2023, then grew by 1.51% to $31.7 billion in 2024, then dropped by 0.18% to $31.6 billion in 2025.
  • The last three reported values for Total Non-Current Liabilities were $31.6 billion (Q4 2025), $31.7 billion (Q4 2024), and $31.2 billion (Q4 2023) per Business Quant data.